A detailed history of Rock Springs Capital Management LP transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Rock Springs Capital Management LP holds 768,776 shares of BPMC stock, worth $72.9 Million. This represents 2.42% of its overall portfolio holdings.

Number of Shares
768,776
Previous 2,460,417 68.75%
Holding current value
$72.9 Million
Previous $265 Million 73.2%
% of portfolio
2.42%
Previous 8.22%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$84.1 - $120.5 $142 Million - $204 Million
-1,691,641 Reduced 68.75%
768,776 $71.1 Million
Q2 2024

Aug 14, 2024

SELL
$85.18 - $108.78 $3.24 Million - $4.14 Million
-38,031 Reduced 1.52%
2,460,417 $265 Million
Q1 2024

May 15, 2024

SELL
$73.17 - $99.79 $28 Million - $38.2 Million
-383,119 Reduced 13.3%
2,498,448 $237 Million
Q4 2023

Feb 14, 2024

BUY
$43.96 - $92.84 $8.63 Million - $18.2 Million
196,273 Added 7.31%
2,881,567 $266 Million
Q3 2023

Nov 14, 2023

BUY
$46.9 - $66.0 $23.4 Million - $32.9 Million
498,622 Added 22.8%
2,685,294 $135 Million
Q2 2023

Aug 14, 2023

BUY
$42.2 - $66.37 $6.48 Million - $10.2 Million
153,624 Added 7.56%
2,186,672 $138 Million
Q1 2023

May 15, 2023

BUY
$37.97 - $50.0 $5.37 Million - $7.08 Million
141,538 Added 7.48%
2,033,048 $91.5 Million
Q4 2022

Feb 14, 2023

BUY
$41.06 - $66.48 $14.5 Million - $23.5 Million
353,315 Added 22.97%
1,891,510 $82.9 Million
Q3 2022

Nov 14, 2022

BUY
$49.93 - $77.7 $27.9 Million - $43.4 Million
559,021 Added 57.09%
1,538,195 $101 Million
Q2 2022

Aug 15, 2022

BUY
$45.23 - $70.15 $1.42 Million - $2.21 Million
31,459 Added 3.32%
979,174 $49.5 Million
Q1 2022

May 16, 2022

BUY
$54.1 - $110.08 $4.76 Million - $9.68 Million
87,960 Added 10.23%
947,715 $60.5 Million
Q4 2021

Feb 14, 2022

BUY
$94.25 - $115.99 $951,548 - $1.17 Million
10,096 Added 1.19%
859,755 $92.1 Million
Q3 2021

Nov 15, 2021

BUY
$80.98 - $109.47 $3.3 Million - $4.47 Million
40,799 Added 5.04%
849,659 $87.4 Million
Q2 2021

Aug 16, 2021

BUY
$82.78 - $101.0 $5.14 Million - $6.27 Million
62,128 Added 8.32%
808,860 $71.1 Million
Q1 2021

May 17, 2021

SELL
$90.71 - $108.28 $8.64 Million - $10.3 Million
-95,268 Reduced 11.31%
746,732 $72.6 Million
Q4 2020

Feb 16, 2021

SELL
$92.08 - $124.48 $10.2 Million - $13.8 Million
-110,773 Reduced 11.63%
842,000 $94.4 Million
Q3 2020

Nov 16, 2020

SELL
$66.45 - $92.7 $482,161 - $672,631
-7,256 Reduced 0.76%
952,773 $88.3 Million
Q2 2020

Aug 14, 2020

BUY
$57.09 - $79.27 $12.7 Million - $17.7 Million
223,029 Added 30.26%
960,029 $74.9 Million
Q1 2020

May 15, 2020

BUY
$48.11 - $82.22 $17.1 Million - $29.2 Million
355,000 Added 92.93%
737,000 $43.1 Million
Q4 2019

Feb 14, 2020

BUY
$66.73 - $82.59 $3.24 Million - $4.01 Million
48,500 Added 14.54%
382,000 $30.6 Million
Q3 2019

Nov 14, 2019

BUY
$72.9 - $101.41 $1.9 Million - $2.64 Million
26,000 Added 8.46%
333,500 $24.5 Million
Q2 2019

Aug 14, 2019

BUY
$73.54 - $97.8 $2.39 Million - $3.18 Million
32,500 Added 11.82%
307,500 $29 Million
Q1 2019

May 15, 2019

BUY
$48.7 - $86.6 $2.99 Million - $5.31 Million
61,342 Added 28.71%
275,000 $22 Million
Q4 2018

Feb 14, 2019

BUY
$45.57 - $74.26 $622,395 - $1.01 Million
13,658 Added 6.83%
213,658 $11.5 Million
Q3 2018

Nov 14, 2018

BUY
$58.91 - $78.32 $58,910 - $78,320
1,000 Added 0.5%
200,000 $15.6 Million
Q2 2018

Aug 14, 2018

BUY
$60.96 - $101.18 $2.51 Million - $4.17 Million
41,247 Added 26.15%
199,000 $12.6 Million
Q1 2018

May 15, 2018

BUY
$73.28 - $102.95 $824,619 - $1.16 Million
11,253 Added 7.68%
157,753 $14.5 Million
Q4 2017

Feb 14, 2018

BUY
$62.91 - $88.32 $3.77 Million - $5.3 Million
60,000 Added 69.36%
146,500 $11 Million
Q3 2017

Nov 14, 2017

BUY
$42.37 - $69.67 $3.67 Million - $6.03 Million
86,500
86,500 $6.03 Million

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.66B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Rock Springs Capital Management LP Portfolio

Follow Rock Springs Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Springs Capital Management LP with notifications on news.